Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

Rhea-AI Summary

Phathom Pharmaceuticals (NASDAQ: PHAT) has issued a clarification regarding a Schedule 13D filing by Frazier Life Sciences. The company emphasized that the upcoming filing includes only administrative changes to the reporting approach and does not represent any reduction in Frazier's ownership position in Phathom.

While the updated filing may show different breakouts of holdings between funds and persons, and changes in warrant treatment may affect certain percentage calculations, these modifications are purely administrative in nature. The company confirms that no actual sale of shares has occurred.

FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom.

While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier’s reporting approach and not to any sale of shares. 

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

What changes were announced in Frazier Life Sciences' 13D filing for Phathom Pharmaceuticals (PHAT)?

The changes are purely administrative in nature, affecting how holdings are reported between funds and persons, and how warrants are treated. There is no actual reduction in Frazier's ownership position in Phathom.

Has Frazier Life Sciences reduced its stake in Phathom Pharmaceuticals (PHAT)?

No, Phathom Pharmaceuticals has explicitly clarified that there has been no sale of shares by any Frazier fund or person. The changes in the 13D filing are purely administrative.

What products does Phathom Pharmaceuticals (PHAT) currently market?

Phathom markets VOQUEZNA® tablets for Non-Erosive GERD and Erosive GERD in adults, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment.

When will the updated Schedule 13D filing for PHAT be submitted?

The updated Schedule 13D filing by Frazier Life Sciences is expected to be filed on August 20, 2025.